Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology-Reference-Cited by-同舟云学术

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Published:2020-04-16 Issue:9 Volume:63 Page:4506-4516
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Moccia Marialuisa¹,Frett Brendan²³,Zhang Lingtian²,Lakkaniga Naga Rajiv²^ORCID,Briggs David C.⁴,Chauhan Rakhee⁴,Brescia Annalisa¹,Federico Giorgia¹,Yan Wei²,Santoro Massimo¹,McDonald Neil Q.⁴⁵,Li Hong-yu²³^ORCID,Carlomagno Francesca¹⁶^ORCID

Affiliation:

1. Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy

2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States

3. Synactix Pharmaceuticals, Inc., Tucson, Arizona 85718, United States

4. Signalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.

5. Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London WC1E 7HX, U.K.

6. Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, 80131 Napoli, Italy

Funder

National Cancer Institute

European Commission

Ministero dell?Istruzione, dell?Universit? e della Ricerca

Associazione Italiana per la Ricerca sul Cancro

University of Arkansas for Medical Sciences

Wellcome Trust

American Thyroid Association